ReviewInternational journal of molecular sciences2026
Hepatotoxic Compounds and Mechanisms of Polygonum Multiflorum: A Narrative Review of Recent Advances.
Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The clinical application of Polygonum multiflorum Thunb. (PM), a widely used traditional Chinese medicine, is increasingly constrained by its idiosyncratic hepatotoxicity. However, the precise chemical material basis (i.e., specific compound classes such as free anthraquinones, stilbene glycosides, and dianthrones) of this toxicity and the underlying synergistic mechanisms remain poorly defined, posing a significant challenge to safety assessment. This review systematically synthesizes the latest research progress over the past five years, aiming to elucidate the multi-component synergistic toxicity network of PM. As of November 2025, over 293 compounds have been characterized from PM, including anthraquinones, stilbene glycosides, and dianthrones. Among these, multiple components-particularly free anthraquinones (e.g., emodin, chrysophanol, physcion), cis-stilbene glycosides, and dianthrones-have been experimentally associated with hepatotoxicity in various in vitro and in vivo studies. However, current evidence is largely derived from in vitro or animal studies, and the quantitative nature of these synergistic interactions, as well as their translation to human clinical settings, remains uncertain. Accumulating evidence indicates that its hepatotoxicity does not originate from a single component but rather results from the synergistic interaction of free anthraquinones, stilbene glycosides, and dianthrones. At the mechanistic level, the toxicity involves a complex network encompassing direct cellular damage, an immune-mediated "triple-hit" cascade, and disruption of bile acid homeostasis. Importantly, traditional processing methods mitigate toxicity by reducing the content of specific toxic components, whereas individual genetic susceptibility (e.g., HLA-B*35:01 allele) appears to be an important contributing factor, although population-based quantitative risk estimates are still lacking in the occurrence of idiosyncratic liver injury. In conclusion, the hepatotoxicity of PM constitutes a multi-component, multi-target, and multi-pathway synergistic network. Future research should prioritize quantifying the toxic contribution of individual components and elucidating the quantitative principles governing their synergy, thereby establishing a robust paradigm for risk assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.